Key Takeaway: Neurogene Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 14 at 7:30 a.m. PT. The management will present an overview of the company and engage in investor meetings. Neurogene focuses on developing genetic medicines for rare neurological diseases and has established a state-of-the-art manufacturing facility in Houston.
Price reaction · baseline $20.16 (2026-01-02 close) · hit pre-market · clean, no other NGNE news in the window
day 0 close
-8.6%
day 1 · peak
-9.2%
day 3
-7.3%
Market Sentiment Analysis
POSITIVE FACTORS
Participation in a prestigious healthcare conference
Opportunity to present innovative gene therapy solutions
Engagement with investors to support future growth
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~28 mo
Minimal dilution risk
Lead asset
NL-201
Phase 1 · Solid Tumor
Full Press Release Details
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the 44thAnnual J.P. Morgan Healthcare Conference.
Format: Management will present a company overview and participate in investor meetingsDate: Wednesday, January 14 at 7:30 a.m. PT
A webcast of the presentation will be accessible from the Investor Relations section of Neurogene’s website under events, where a replay of the event will also be available for a limited time.
About NeurogeneThe mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visitwww.neurogene.com.
Frequently Asked Questions
When will Neurogene present at the conference?
Neurogene will present on January 14 at 7:30 a.m. PT.
What is the focus of Neurogene's development?
Neurogene focuses on genetic medicines for rare neurological diseases.
Where is Neurogene's manufacturing facility located?
Neurogene has a state-of-the-art manufacturing facility in Houston, Texas.
How can investors access the presentation?
The presentation will be available via webcast on Neurogene's Investor Relations website.